Earnings Report /

Ibn Sina Pharmaceutical Industry Ltd: Q2 FY21: c12% yoy NPAT growth driven by c23% yoy revenue growth; reiterate Buy

  • Standalone earnings growth was mainly driven by c23% yoy revenue growth in Q2 FY21

  • Higher opex and higher effective tax rate partially offset the benefit of the top line growth

  • We continue Buy for IBNSIN (ETR 28.6%) with TP BDT 310

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

IDLC Securities
26 January 2021
Published by